Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ).
China NT Pharma Group Co., Ltd. has completed a connected transaction involving loan capitalization through the subscription of new shares. This transaction led to the issuance of 410,156,509 new shares, which significantly altered the company’s shareholding structure, with Subscriber A and Subscriber B now holding a combined 75% of the issued share capital. The transaction, finalized on February 21, 2025, will not yield cash proceeds as the subscription price was settled by offsetting existing debts, thus impacting the company’s financial strategy and stakeholder interests.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd., incorporated in the Cayman Islands, operates primarily in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products in Hong Kong and China.
YTD Price Performance: -14.81%
Average Trading Volume: 191,580
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$57.1M
See more insights into 1011 stock on TipRanks’ Stock Analysis page.
